Inhibiting Hsp90 sensitizes MDR ovarian cancer cells to chemotherapy by impairing the AKT/GSK3β/β-catenin signaling pathway, highlighting Hsp90 as a potential therapeutic target [129]. Here, HSP90AA1 is linked to ovarian cancer.